MicroRNA-29a Is a Candidate Biomarker for Alzheimer’s Disease in Cell-Free Cerebrospinal Fluid

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1559-1182
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
MicroRNA-29a Is a Candidate Biomarker for Alzheimer’s Disease in Cell-Free Cerebrospinal Fluid ; volume:53 ; number:5 ; day:21 ; month:4 ; year:2015 ; pages:2894-2899 ; date:7.2016
Molecular neurobiology ; 53, Heft 5 (21.4.2015), 2894-2899, 7.2016

Creator
Müller, Mareike
Contributor
Jäkel, Lieke
Bruinsma, Ilona B.
Claassen, Jurgen A.
Kuiperij, H. Bea
Verbeek, Marcel M.
SpringerLink (Online service)

DOI
10.1007/s12035-015-9156-8
URN
urn:nbn:de:1111-2016061118994
Rights
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:48 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Müller, Mareike
  • Jäkel, Lieke
  • Bruinsma, Ilona B.
  • Claassen, Jurgen A.
  • Kuiperij, H. Bea
  • Verbeek, Marcel M.
  • SpringerLink (Online service)

Other Objects (12)

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer’s Disease

Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer’s Disease

Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease

Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease

Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers

Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers

Metabolite profiling of Alzheimer's disease cerebrospinal fluid

Metabolite profiling of Alzheimer's disease cerebrospinal fluid

Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease

Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease

Diagnostic and progression biomarkers in cerebrospinal fluid of Alzheimer’s disease patients

Diagnostic and progression biomarkers in cerebrospinal fluid of Alzheimer’s disease patients

APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease

APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease

Cerebrospinal fluid lipidomic fingerprint of obstructive sleep apnoea in Alzheimer’s disease

Cerebrospinal fluid lipidomic fingerprint of obstructive sleep apnoea in Alzheimer’s disease

Plasma and cerebrospinal fluid cholesterol esterification is hampered in Alzheimer’s disease

Plasma and cerebrospinal fluid cholesterol esterification is hampered in Alzheimer’s disease

Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer’s disease

Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer’s disease

Associations of cerebrospinal fluid amyloidogenic nanoplaques with cytokines in Alzheimer’s disease

Associations of cerebrospinal fluid amyloidogenic nanoplaques with cytokines in Alzheimer’s disease

Related objects